Cognitive impairments in schizophrenia and their impact on oxidative stress

The article is devoted to modern concepts of cognitive disorders in schizophrenia. Neurocognitive deficits can be expressed in impaired attention, auditory memory, motor skills, working memory, processing speed and executive function. The attention of researchers is currently being paid to the violation of the speed of information processing and character encoding that can lead to impaired social functioning in patients with schizophrenia. Two hypotheses about the dynamics of neurocognitive impairments in schizophrenia are also considered: the theory of «static encephalopathy» and progressive impairment of cognitive functions.

This review evaluates the results of a comparative analysis of the effectiveness of first and second generation antipsychotics in the treatment of cognitive dysfunction. As a result of the analysis of the available data, it was concluded that first-generation antipsychotics most likely do not directly impair cognitive abilities, but they can do so indirectly, due to the simultaneous use of anticholinergic drugs that compromise some neurocognitive abilities. Second-generation antipsychotics have an advantage over first-generation drugs, however, it has been argued that most antipsychotics lead to a slight improvement in cognitive functioning, and there is no specific effect on its specific domains.

An analysis of data on the relationship between oxidative stress markers and psychopathological characteristics and cognitive profile of patients with schizophrenia was carried out. In particular, the mechanism of stress-induced cell death in the prefrontal and anterior frontal regions and a decrease in brain volume in these regions, leading to a decrease in cognitive and executive functions, are considered. In addition, the mechanisms of association of redox imbalance with brain-derived neurotrophic factor (BDNF) depletion, hypofunction of the NMDA receptor, changes in the level of pro-inflammatory cytokines, neurogenesis, and cell apoptosis were considered.

1. Gurovich IYa, Shmukler AB, Lyubov EB, Magomedova MV, Belokurova EA, Dorodnova AS, Movina LG. Clinical-social, neurocognitive and pharmacoeconomic evaluation of seroquel therapy in patients with a first psychotic episode (second phase of the study). Social’naya i klinicheskaya psihiatriya. 2004;14(4):44–51. (In Russ.).

2. Gurovich IYa, Shmukler AB, Sargsyan GR, Dorodnova AS, Kalashnikova II, Movina LG. Comprehensive assessment of pharmacotherapy in patients with a first psychotic episode: the use of sertindole. Social’naya i klinicheskaya psihiatriya. 2010;20(1): 25–32. (In Russ.).

3. Zaitseva YuS, Korsakova NK. Dynamics of neurocognitive deficit in patients with varying degrees of progression of schizophrenia during the first attacks and during a 5-year follow-up. Social’naya i klinicheskaya psihiatriya. 2008;18(2):15-25. (In Russ.).

4. Ivanov M.V., Yanushko M.G. Farmakoterapevticheskij podhod k korrekcii kognitivnyh narushenij pri shizofrenii (metodicheskie rekomendacii dlya vrachej). SPb.: NIPNI im. V.M. Bekhtereva, 2011. (In Russ.).

5. Kazakovtsev B.A., Tvorogova N.A., Nikolaeva T.A., Demcheva N.K. Rasprostranennost’ psihicheskih rasstrojstv v naselenii Rossijskoj Federacii v 2011 godu (analiticheskij obzor)– M.: FGBU «FMICPN» Minzdrava Rossii, 2014. (In Russ.).

6. Magomedova M.V. Sootnoshenie social’nogo funkcionirovaniya i nejrokognitivnogo deficita u bol’nyh shizofreniej i shizoaffektivnym rasstrojstvom na rannem i otdalennom etape bolezni: dis. … kand. med. nauk: 14.00.18. M. 2003. (In Russ.).

7. Movina L.G. Psihosocial’naya terapiya bol’nyh shizofreniej i rasstrojstvami shizofrenicheskogo spektra s pervymi psihoticheskimi epizodamiyu Avtoref. dis. na soisk. uchen. step. kand. med. nauk, 2005. (In Russ.).

8. Mosolov SN. Modern antipsychotic pharmacotherapy of schizophrenia. Russkij medicinskij zhurnal. 2004;12(10):646-652. (In Russ.).

9. Mosolov SN, Kabanov SО, Karimulaev IA, Ryvkin PV. Reduction of cognitive impairment in patients with the first episode of schizophrenia and chronic course of the disease in the treatment of quetiapine. Psihiatriya i psihofarmakoterapiya. 2005;1:6-11. (In Russ.).

10. Mosolov S.N., Kalinin V.V., Eremin A.V. Sravnitel’naya effektivnost’ i perenosimost’ novogo pokoleniya antipsihoticheskih sredstv pri lechenii obostrenij shizofrenii (meta-analiz original’nyh issledovanij olanzapina, risperidona, kvetiapina, klozapina i galoperidola). Novye dostizheniya v terapii psihicheskih zabolevanij. M., 2002. (In Russ.).

11. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsihoticheskaya farmakoterapiya shizofrenii: ot nauchnyh dannyh k klinicheskim rekomendaciyam. Biologicheskie metody terapii psihicheskih rasstrojstv. Dokazatel’naya medicina — klinicheskoj praktike. M., 2012. (In Russ.).

12. Panina A.N. Zakonomernosti izmenenij pokazatelej nejrokognitivnyh funkcij pri paranoidnoj shizofrenii pri terapii diss ... kand. med. nauk. 2007. (In Russ.).

13. Semenova N.V., Vuks A.Ya., Chernov P.D., Lysenko I.S. Zabolevaemost’ psihicheskimi rasstrojstvami naseleniya Severo-Zapadnogo federal’nogo okruga: Statisticheskie materialy i analiz. SPb: 2018. (In Russ.)

14. Sofronov AG, Spikina AA, Savelyev AP. Neurocognitive deficits and social functioning in schizophrenia: a comprehensive assessment and possible correction. Social’naya i klinicheskaya psihiatriya. 2012;22(1):33–37. (In Russ.).

15. Yanushko M.G. Antipsihoticheskaya terapiya shizofrenii: klinicheskie i kognitivnye aspekty: diss ... kand. med. nauk. SPb: 2008. (In Russ.).

16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). 2013.

17. Andersen R., Fagerlund B., Rasmussen H., Ebdrup B.H., Aggernaes B., Gade A., Oranje B., Glenthoj B. The influence of impaired processing speed on cognition in first-episode antipsychotic naive schizophrenic patients. European Psychiatry. 2013;28:332–339. https://doi.org/10.1016/j.eurpsy.2012.06.003

18. Andreasen N.C., Nopoulos P., O’Leary D.S. Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol. Psychiatr. 1999;46(7):908–920. doi: 10.1016/s0006-3223(99)00152-3

19. Appels M.C.M., Sitskoorn M.M., Westers P., Lems E., Kahn R.S. Cognitive dysfunctions in parents of schizophrenic patients parallel the deficits found in patients. Schizophrenia Research. 2003;63(3): 285–293. https://doi.org/10.1016/S0920-9964(02)00342-0

20. Barnes T.R., Drake R., Paton C., Cooper S.J., Deakin B., Ferrier I.N. et. al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78. doi: 10.1177/0269881119889296

21. Bechi M., Spangaro M., Agostoni G., Bosinelli F., Buonocore M., Bianchi L. et. al. Intellectual and cognitive profiles in patients affected by schizophrenia. J Neuropsychol. 2018;13(3):589-602. doi: 10.1111/jnp.12161

22. Beeraka N.M., Avila-Rodriguez M.F., Aliev G. Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia. Mol Neurobiol. 2022. doi: 10.1007/s12035-021-02703-4

23. Bell M.D., Mishara A.L. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr. Res. 2006;81(1):17-27. doi: 10.1016/j.schres.2005.09.016

24. Berman, K. F., Weinberger, D. R., Shelton, R. C. & Zec, R. F. A relationship between anatomical and physiological brain pathology in schizophrenia: lateral cerebral ventricular size predicts cortical blood flow. American Journal of Psychiatry. Am J Psychiatry. 1987;144(10):1277-82. doi: 10.1176/ajp.144.10.1277

25. Beyene G.M., Legas G., Azale T., Abera M., Asnakew S. The magnitude of disability in patients with schizophrenia in North West Ethiopia: A multicenter hospital-based cross-sectional study. Heliyon. 2021;7(5):e07053. doi: 10.1016/j.heliyon.2021.e07053

26. Blanchard J.J., Neale J.M. The neuropsychological signature of schizophrenia: generalized or differential deficit? Am J Psychiatr. 1994;151(1): 40–48.

27. Bosia M., Buonocore M., Bechi M., Spangaro M., Pigoni A., Croci M. et. al. Cognitive remediation and functional improvement in schizophrenia: is it a matter of size? Eur Psychiatry. 2017;40:26-32. doi: 10.1016/j.eurpsy.2016.06.007

28. Braw Y., Bloch Y., Mendelovich S., Ratzoni G., Gal G., Harari H., Tripto A., Levkovitz Y. Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients. Schizophr Bull. 2008;34(3):544-54. doi: 10.1093/schbul/sbm115

29. Carrión R.E., Walder D.J., Auther A.M., McLaughlin D., Zyla H.O., Adelsheim S. et. al. McFarlane W.R., Cornblatt B.A. From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline. J Psychiatr Res. 2018;96:231-238. doi:10.1016/j.jpsychires.2017.10.014

30. Cecerska-Heryć E., Polikowska A., Serwin N., Roszak M., Grygorcewicz B., Heryć R., Michalczyk A., Dołęgowska B. Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem Int. 2022;153:105269. doi: 10.1016/j.neuint.2021.105269

31. Censits D.M., Ragland J.D., Gur R.C. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia. Schizophr Res. 1997;24(3):289–298. doi: 10.1016/s0920-9964(96)00091-6

32. Cornblatt B.A., Carrión R.E., Auther A., McLaughlin D., Olse, R.H., John M., Correll C.U. Psychosis prevention: a modified clinical high risk perspective from the recognition and prevention (RAP) program. Am J Psychiatry. 2015;172(10):986-94. doi: 10.1176/appi.ajp.2015.13121686

33. Cummings J.L. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50(8):873-80. doi: 10.1001/archneur.1993.00540080076020

34. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S. et. al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806

35. Désaméricq G., Schurhoff F., Meary A., Szöke A., Macquin-Mavier I., Bachoud-Lévi A.C., Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014;70(2):127-34. doi: 10.1007/s00228-013-1600-y

36. Dickinson D., Ramsey M. E., Gold J. M. Overlooking the obvious: A meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64(5):532-42. doi: 10.1001/archpsyc.64.5.532

37. Durgam S., Cutler A.J., Lu K., Migliore R., Ruth A., Laszlovszky I., Németh G., Meltzer H.Y. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574-82. doi: 10.4088/JCP.15m09997

38. Fleischhacker W., Galderisi S., Laszlovszky I., Szatmári B., Barabássy Á., Acsai K. et. al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1-9. doi: 10.1016/j.eurpsy.2019.01.015

39. Fraguas D., Díaz-Caneja C.M., RodríguezQuiroga A., Arango C. Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2017;20(6): 435–444. doi: 10.1093/ijnp/pyx015

40. Fusar-Poli P., Deste G., Smieskova R., Barlati S., Yung A.R., Howes O. et. al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69(6):562-71. doi: 10.1001/archgenpsychiatry.2011.1592

41. Gaebel W., Zielasek J., Cleveland H.R. Psychotic Disorders in ICD-11. Asian J Psychiatr. 2013;6(3):263-5. doi: 10.1016/j.ajp.2013.04.002

42. Gallhofer B., Jaanson P., Mittoux A., Tanghøj P., Lis S., Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry. 2007;40(6):275-86. doi: 10.1055/s-2007-990291

43. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7

44. Gold S., Arndt S., Nopoulos P., O’Leary D.S., Andreasen N.C. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry. 1999;156(9):1342-8. doi: 10.1176/ajp.156.9.1342

45. Gonzalez-Liencres C., Tas C., Brown E.C., Erdin S., Onur E., Cubukcoglu Z. et. al. Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition. BMC Psychiatry. 2014;14:268. doi: 10.1186/s12888-014-0268-x

46. Green M.F., Harvey P.D. Cognition in schizophrenia: Past, present, and future. Schizophr Res Cogn. 2014;1(1):e1-e9. doi: 10.1016/j.scog.2014.02.001

47. Gu F., Chauhan V., Chauhan A. Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care. 2015;18(1):89-95. doi: 10.1097/MCO.0000000000000134

48. Hartman M., Steketee M.C., Silva S., Lanning K., McCann H. Working memory and schizophrenia: evidence for slowed encoding. Schizophr Res. 2003;59(2-3):99-113. doi: 10.1016/s0920-9964(01)00366-8

49. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158(2):176-84. doi: 10.1176/appi.ajp.158.2.176

50. Harvey P.D., Siu C.O., Hsu J., Cucchiaro J., Maruff P., Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23(11):1373-82. doi: 10.1016/j.euroneuro.2013.08.003

51. Harvey P.D., Siu C.O., Loebel A.D. Insight and Treatment Outcomes in Schizophrenia: Posthoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR. Innov Clin Neurosci. 2017;14(11-12):23-29.

52. Harvey P.D., Parrella M., White L., Mohs R.C., Davidson M., Davis K.L. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 1999;35(1):77-84. doi: 10.1016/s0920-9964(98)00109-1

53. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004;65(3):361-72.

54. Heaton R.K., Velin R.A., McCutchan J.A., Gulevich S.J., Atkinson J.H., Wallace M.R. et. al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med. 1994;56(1):8-17. doi: 10.1097/00006842-199401000-00001

55. Jahshan C., Heaton R.K., Golshan S., Cadenhead K.S. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology. 2010;24(1):109-120. doi: 10.1037/a0016791

56. Juckel G., de Bartolomeis A., Gorwood P., Mosolov S., Pani L., Rossi A., Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1867-78. doi: 10.2147/NDT.S61672

57. Keefe R.S., Poe M., Walker T.M., Kang J.W., Harvey P.D. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006;163(3):426-32. doi: 10.1176/appi.ajp.163.3.426

58. Kim G.H., Kim J.E., Rhie S.J., Yoon S. The Role of Oxidative Stress in Neurodegenerative Diseases. Exp Neurobiol. 2015;24(4):325-40. doi: 10.5607/en.2015.24.4.325

59. Kim S.J., Jung D.U., Moon J.J., Jeon D.W., Seo Y.S., Jung S.S., Lee Y.C., Kim J.E., Kim Y.S. Relationship between disability self-awareness and cognitive anddaily living function in schizophrenia. Schizophr Res Cogn. 2020;23:100192. doi: 10.1016/j.scog.2020.100192

60. Kitabatake Y., Hikida T., Watanabe D., Pastan I., Nakanishi S. Impairment of reward-related learning by cholinergic cell ablation in the striatum. Proc Natl Acad Sci U S A. 2003;100(13):7965-70. doi: 10.1073/pnas.1032899100

61. Kraepelin, E. Dementia Praecox and Paraphrenia. Robert E. Krieger Publishing Co., LoCo, Huntington, New York. 1971.

62. Kucharska-Pietura K., Tylec A., Czernikiewicz A., Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med Sci Monit. 2012;18(1):CR44-49. doi: 10.12659/msm.882202

63. Laszlovszky I., Barabássy Á., Németh G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5

64. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O. et. al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33(9):2187-99. doi: 10.1038/sj.npp.1301624

65. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 1999;37(1):1-11. doi: 10.1016/s0920-9964(98)00145-5

66. Leeson V.C., Barnes T.R., Harrison M., Matheson E., Harrison I., Mutsatsa S.H., Ron M.A., Joyce E.M. The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. Schizophr Bull. 2010;36(2):400-9. doi: 10.1093/schbul/sbn100

67. Maas D.A., Vallès A., Martens G.J.M. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry. 2017;7(7):e1171. doi: 10.1038/tp.2017.MarinO. Developmental timing and critical windows for the treatment of psychiatric disorders. Nat Med. 2016;22:1229–1238. doi: 10.1038/nm.4225

68. Martinez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Mico J.A., Fernandez M., Echevarria E. et. al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res. 2012;137(1–3):66–72. doi: 10.1016/j.schres.2012.03.004

69. Maslenikov N., Tsukarzi E., Mosolov S. Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression in schizophrenia patients. Ann Gen Psych. 2008;7(1): 312.

70. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E. et. al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One. 2008;3(4):e1944. doi: 10.1371/journal.pone.0001944

71. Meltzer H.Y., Share D.B., Jayathilake K., Salomon R.M., Lee M.A. Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. J Clin Psychopharmacol. 2020;40(3):240-249. doi: 10.1097/JCP.0000000000001205

72. Miller B.J., Pikalov A., Siu C.O., Tocco M., Tsai J., Harvey P.D., Newcomer J.W., Loebel A. Insight and Treatment Outcomes in Schizophrenia: Posthoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR.. Compr Psychiatry. 2020;102:152195. doi: 10.1016/j.comppsych.2020.152195

73. Neill J.C., Grayson B., Kiss B., Gyertyán I., Ferguson P., Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26(1):3-14. doi: 10.1016/j.euroneuro.2015.11.016

74. Newton D.F., Naiberg M.R., Goldstein B.I. Oxidative stress and cognition amongst adults without dementia or stroke: implications for mechanistic and therapeutic research in psychiatric disorders. Psychiatry Res 2015;227(2–3):127–34. doi: 10.1016/j.psychres.2015.03.038

75. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72(1):29-39. doi: 10.1016/j.schres.2004.09.007

76. Nuyen J., Sitskoorn M.M., Cahn W., Kahn R.S. Verbal memory in first-episode schizophrenia: heterogeneity in performance? J Int Neuropsychol Soc. 2005;11(2):152-62. doi: 10.1017/s1355617705050162

77. Ogino S., Miyamoto S., Tenjin T., Kitajima R., Ojima K., Miyake N. et. al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):78-83. doi: 10.1016/j.pnpbp.2010.08.030

78. Ojeda N., Sánchez P., Peña J., Elizagárate E., Yoller A.B., Gutiérrez-Fraile M., Ezcurra J., Napal O. An explanatory model of quality of life in schizophrenia: the role of processing speed and negative symptoms. Actas Esp Psiquiatr. 2012;40(1):10-8.

79. Ojeda N., Sánchez P., Peña J., Elizagárate E., Yoller A.B., Larumbe J., Gutiérrez M., Casais L., Ezcurra J. Verbal fluency in schizophrenia: does cognitive performance reflect the same underlying mechanisms in patients and healthy controls? J Nerv Ment Dis. 2010;198(4):286-91. doi: 10.1097/NMD.0b013e3181d61748

80. Manna P., Jain S.K. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated HealthRisks: Causes and Therapeutic Strategies. Metab Syndr Relat Disord. 2015;13(10):423-44. doi: 10.1089/met.2015.0095

81. Prouteau A., Verdoux H., Briand C., Lesage A., Lalonde P., Nicole L., Reinharz D., Stip E. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res. 2005;77(2-3):343-53. doi: 10.1016/j.schres.2005.03.001

82. Pukrop R., Ruhrmann S., Schultze-Lutter F., Bechdolf A., Brockhaus-Dumke A., Klosterkötter J. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res. 2007;92(1-3):116-25. doi: 10.1016/j.schres.2007.01.020

83. Rodríguez-Sánchez J.M., Crespo-Facorro B., González-Blanch C., Perez-Iglesias R., Vázquez-Barquero J.L.; PAFIP Group Study. Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. Br J Psychiatry Suppl. 2007;51:107-10. doi: 10.1192/bjp.191.51.s107

84. Ruiz J.C., Soler M.J., Fuentes I., Tomás P. Intellectual functioning and memory deficits in schizophrenia. Compr Psychiatry. 2007;48(3):276-82. doi: 10.1016/j.comppsych.2006.11.002

85. Samuni Y., Goldstein S., Dean O.M., Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830(8):4117-29. doi: 10.1016/j.bbagen.2013.04.016

86. Sánchez P., Ojeda N., Peña J., Elizagárate E., Yoller A.B., Gutiérrez M., Ezcurra J. Predictors of longitudinal changes in schizophrenia: the role of processing speed. J Clin Psychiatry. 2009;70(6):888-96. doi: 10.4088/JCP.08m04294

87. Seidman L.J., Shapiro D.I., Stone W.S., Woodberry K.A., Ronzio A., Cornblatt B.A. et. al. Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. JAMA Psychiatry. 2016;73(12):1239-1248. doi: 10.1001/jamapsychiatry.2016.2479

88. Şimşek Ş., Gençoğlan S., Yüksel T., Kaplan İ., Alaca R., Aktaş H. Oxidative Stress and DNA Damage in Untreated First-Episode Psychosis in Adolescents. Neuropsychobiology. 2016;73(2):92-7. doi: 10.1159/000444488

89. Slack S.E., Pezet S., McMahon S.B., Thompson S.W.N., Malcangio M. Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. Eur J Neurosci 2004;20(7):1769–78. doi: 10.1111/j.1460-9568.2004.03656.x

90. Takeuchi H., Suzuki T., Remington G., Bies R.R., Abe T., Graff-Guerrero A. et. al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013;39(5):993-8. doi: 10.1093/schbul/sbt090

91. Talarowska M., Gałecki P., Maes M., Gardner A., Chamielec M., Orzechowska A., Bobińska K., Kowalczyk E. Malondialdehyde plasma concentration correlates with declarative and working memory in patients with recurrent depressive disorder. Mol Biol Rep. 2012;39(5):5359-66. doi: 10.1007/s11033-011-1335-8

92. Vaskinn A., Ueland T., Melle I., Agartz I., Andreassen O.A., Sundet K. Neurocognitive Decrements are Present in Intellectually Superior Schizophrenia. Front Psychiatry. 2014;5:45. doi: 10.3389/fpsyt.2014.00045

93. Weinberger D. R., Kleinman, J. E. Observations on the brain in schizophrenia. Psychiatry update: the American Psychiatric Association Annual Review. 1986;5:147-149.

94. Welham J., Isohanni M., Jones P., McGrath J. The antecedents of schizophrenia: a review of birth cohort studies. Schizophr Bull. 2009;35(3):603-23. doi: 10.1093/schbul/sbn084

95. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457-72. doi: 10.1017/S146114570500516X

96. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-85. doi: 10.1176/appi.ajp.2010.10060855

97. Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des Devel Ther. 2012;6:107-15. doi: 10.2147/DDDT.S11180

98. Zavodnick A.D., Ali R. N-acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review. Psychiatr Q 2014;85(2):177–85. doi: 10.1007/s11126-013-9281-3

99. Zhang X.Y., Chen D.C., Tan Y.L., Tan S.P., Wang Z.R., Yang F.D. et. al. The interplay between BDNF and oxidative stress in chronic schizophrenia. Psychoneuroendocrinology. 2015;51:201-8. doi: 10.1016/j.psyneuen.2014.09.029

100. Zhang X.Y., Yao J.K. Oxidative stress and therapeutic implications in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:197-9. doi: 10.1016/j.pnpbp.2013.03.003. Epub 2013 Mar 21.

101. Zhang T., Li H., Stone W.S., Woodberry K.A., Seidman L.J., Tang Y. et. al. Neuropsychological Impairment in Prodromal, First-Episode, and Chronic Psychosis: Assessing RBANS Performance. PLoS One. 2015;10(5):e0125784. doi: 10.1371/journal.pone.0125784